Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · IEX Real-Time Price · USD
74.80
+0.61 (0.82%)
At close: May 3, 2024, 4:00 PM
76.30
+1.50 (2.01%)
After-hours: May 3, 2024, 4:19 PM EDT
Axsome Therapeutics Revenue
In the year 2023, Axsome Therapeutics had annual revenue of $270.60M with 440.80% growth. Revenue in the quarter ending December 31, 2023 was $71.53M with 193.50% year-over-year growth.
Revenue (ttm)
$270.60M
Revenue Growth
+440.80%
P/S Ratio
13.10
Revenue / Employee
$496,514
Employees
545
Market Cap
3.54B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
Dec 31, 2022 | 50.04M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Select Medical Holdings | 6.66B |
Oscar Health | 5.86B |
PACS Group | 3.11B |
Integer Holdings | 1.63B |
RadNet | 1.62B |
Prestige Consumer Healthcare | 1.13B |
iRhythm Technologies | 492.68M |
Ultragenyx Pharmaceutical | 434.25M |
AXSM News
- 2 days ago - Axsome Therapeutics Recognizes May as Mental Health Awareness Month - GlobeNewsWire
- 18 days ago - Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting - GlobeNewsWire
- 23 days ago - Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 - GlobeNewsWire
- 4 weeks ago - Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial - Reuters
- 5 weeks ago - Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy - GlobeNewsWire
- 6 weeks ago - Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder - GlobeNewsWire